Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313408045> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4313408045 endingPage "165.21" @default.
- W4313408045 startingPage "165.21" @default.
- W4313408045 abstract "Abstract Tuberculosis (TB) patients diagnosed as drug-resistant TB have limited treatment options. Nix-TB trial is testing three-oral-drugs, namely Bedaquiline (B), Pretomanid (Pa) and Linezolid (L) (BPaL regimen) against drug-resistant TB. The BPaL regimen shows excellent favorable outcomes, but toxic effects are observed due to the long-term administration of Linezolid. Spectinamide-1599 (1599) is a potent protein inhibitor of Mycobacterium tuberculosis (Mtb) without known adverse effects and cross-resistance with other TB drugs. We hypothesized that inhaled 1599 could replace L in the BPaL regimen and provide similar or higher efficacy as BPaS regimen. Therefore, we tested BPaL and BPaS regimens in Balb/c (TB resistant) and C3HeB/FeJ (TB susceptible) mice infected with low-dose Mtb, and evaluated bacterial burden using colony-forming units (CFUs). Compared to untreated mice, CFUs in lungs of BPaL and BPaS treated Balb/c mice were decreased by >1 and 5 logs after 2- and 4-weeks treatment, respectively. In C3HeB/FeJ mice, 4-weeks of BPaL and BPaS treatment decreased CFUs by >3 logs compared to untreated control. However, no statistically significant differences were observed between treatment groups in both the mice strains. Cellular profiling using flow cytometry showed increased monocytes (CD11bhi CD14hi CCR2hi) and neutrophils (CD11b+ Ly6G+) in the bone marrow of BPaS mice compared to BPaL. These results along with cytokine profiling of the two treatment groups showed enhanced inflammatory response in BPaS mice than BPaL. We concluded that inhaled 1599 is a potential replacement for Linezolid if combined as BPaS regimen, and further studies are warranted. This project was funded by National Institute of Health under the funding number NIH-NIAID-Allergy and Infect Diseases AI120670." @default.
- W4313408045 created "2023-01-06" @default.
- W4313408045 creator A5003261496 @default.
- W4313408045 creator A5008410969 @default.
- W4313408045 creator A5031235666 @default.
- W4313408045 creator A5044585460 @default.
- W4313408045 creator A5049438472 @default.
- W4313408045 creator A5054137351 @default.
- W4313408045 creator A5058057231 @default.
- W4313408045 creator A5071846305 @default.
- W4313408045 creator A5083296294 @default.
- W4313408045 date "2022-05-01" @default.
- W4313408045 modified "2023-10-18" @default.
- W4313408045 title "Preclinical <i>in vivo</i> assessment of replacing linezolid for spectinamide-1599 in the Nix-TB regimen" @default.
- W4313408045 doi "https://doi.org/10.4049/jimmunol.208.supp.165.21" @default.
- W4313408045 hasPublicationYear "2022" @default.
- W4313408045 type Work @default.
- W4313408045 citedByCount "0" @default.
- W4313408045 crossrefType "journal-article" @default.
- W4313408045 hasAuthorship W4313408045A5003261496 @default.
- W4313408045 hasAuthorship W4313408045A5008410969 @default.
- W4313408045 hasAuthorship W4313408045A5031235666 @default.
- W4313408045 hasAuthorship W4313408045A5044585460 @default.
- W4313408045 hasAuthorship W4313408045A5049438472 @default.
- W4313408045 hasAuthorship W4313408045A5054137351 @default.
- W4313408045 hasAuthorship W4313408045A5058057231 @default.
- W4313408045 hasAuthorship W4313408045A5071846305 @default.
- W4313408045 hasAuthorship W4313408045A5083296294 @default.
- W4313408045 hasConcept C126322002 @default.
- W4313408045 hasConcept C142724271 @default.
- W4313408045 hasConcept C197934379 @default.
- W4313408045 hasConcept C203014093 @default.
- W4313408045 hasConcept C2777975735 @default.
- W4313408045 hasConcept C2778980435 @default.
- W4313408045 hasConcept C2779489039 @default.
- W4313408045 hasConcept C2780544761 @default.
- W4313408045 hasConcept C2781069245 @default.
- W4313408045 hasConcept C2781413609 @default.
- W4313408045 hasConcept C2781414143 @default.
- W4313408045 hasConcept C523546767 @default.
- W4313408045 hasConcept C54355233 @default.
- W4313408045 hasConcept C71924100 @default.
- W4313408045 hasConcept C86803240 @default.
- W4313408045 hasConcept C98274493 @default.
- W4313408045 hasConceptScore W4313408045C126322002 @default.
- W4313408045 hasConceptScore W4313408045C142724271 @default.
- W4313408045 hasConceptScore W4313408045C197934379 @default.
- W4313408045 hasConceptScore W4313408045C203014093 @default.
- W4313408045 hasConceptScore W4313408045C2777975735 @default.
- W4313408045 hasConceptScore W4313408045C2778980435 @default.
- W4313408045 hasConceptScore W4313408045C2779489039 @default.
- W4313408045 hasConceptScore W4313408045C2780544761 @default.
- W4313408045 hasConceptScore W4313408045C2781069245 @default.
- W4313408045 hasConceptScore W4313408045C2781413609 @default.
- W4313408045 hasConceptScore W4313408045C2781414143 @default.
- W4313408045 hasConceptScore W4313408045C523546767 @default.
- W4313408045 hasConceptScore W4313408045C54355233 @default.
- W4313408045 hasConceptScore W4313408045C71924100 @default.
- W4313408045 hasConceptScore W4313408045C86803240 @default.
- W4313408045 hasConceptScore W4313408045C98274493 @default.
- W4313408045 hasIssue "1_Supplement" @default.
- W4313408045 hasLocation W43134080451 @default.
- W4313408045 hasOpenAccess W4313408045 @default.
- W4313408045 hasPrimaryLocation W43134080451 @default.
- W4313408045 hasRelatedWork W2213844652 @default.
- W4313408045 hasRelatedWork W2922915119 @default.
- W4313408045 hasRelatedWork W2949735449 @default.
- W4313408045 hasRelatedWork W3121694384 @default.
- W4313408045 hasRelatedWork W3164976415 @default.
- W4313408045 hasRelatedWork W4214646668 @default.
- W4313408045 hasRelatedWork W4293282409 @default.
- W4313408045 hasRelatedWork W4293842430 @default.
- W4313408045 hasRelatedWork W4313857350 @default.
- W4313408045 hasRelatedWork W4315618750 @default.
- W4313408045 hasVolume "208" @default.
- W4313408045 isParatext "false" @default.
- W4313408045 isRetracted "false" @default.
- W4313408045 workType "article" @default.